Breaking news out of Pharmacy Times today is that the FDA just sent the green light to diabetes drug combo, AstraZeneca’s fixed-dose combination drug, Qtern (10 mg dapagliflozin
and 5 mg saxagliptin), for the treatment of type 2 diabetes as an
adjunct to diet and exercise.
Jennifer Barrett writes, "The drug is indicated to improve blood sugar levels in adults with type 2
diabetes who have been unable to achieve glycemic control with
dapagliflozin or who are already treated with dapagliflozin and
saxagiptin." An oral medicine option will also be available to patients who may benefit from controlled blood sugar levels with a once daily tablet.
Read more on the story by clicking HERE!
Performance Pharmacy Solutions (PPS) is a unique pharmacy benefit procurement platform developed by HORIZON Health Ventures to
efficiently and effectively place, manage and oversee our self-funded
client's pharmacy benefit management programs. The PPS platform provides
turnkey solutions with proven market-leading PBM partners that offer,
on average, 10-15% savings.
No comments:
Post a Comment